Education
About Us
Working with TipRanks
Follow Us
Protalix Biotherapeutics (PLX)
:PLX
PLX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.89 - $3.10
Previous CloseN/A
Volume368.29K
Average Volume (3M)589.01K
Market Cap
$121.99M
Enterprise Value$92.23M
Total Cash (Recent Filing)$33.40M
Total Debt (Recent Filing)$5.35M
Price to Earnings (P/E)21.2
Beta0.70
Next Earnings
Nov 17, 2025EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding79,732,120
10 Day Avg. Volume651,020
30 Day Avg. Volume589,009
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.76
Enterprise Value/Revenue1.49
Enterprise Value/Gross Profit2.59
Enterprise Value/Ebitda8.74
Forecast
1Y Price Target
$8.25Price Target Upside425.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Capital StructureCapital structure now looks exceptionally clean, with no remaining long-term debt outstanding.
Global ApprovalsPegunigalsidase alfa-iwxj is now approved across 23 territories globally for the treatment of Fabry disease.
Revenue GrowthSales to Chiesi rose $8M during 2Q25 vs. the year-ago period.
Bears Say
Cash FlowThe company has $34.7M in cash and short-term bank deposits, expected to be sufficient to fund operations to cash flow breakeven.
Revenue ShortfallProtalix reported 1Q25 revenues from selling goods of $10M vs. forecast of $21.6M, attributed to choppiness in royalty-based revenue.
Protalix News
PLX FAQ
What was Protalix Biotherapeutics’s price range in the past 12 months?
Protalix Biotherapeutics lowest stock price was $0.89 and its highest was $3.10 in the past 12 months.
What is Protalix Biotherapeutics’s market cap?
Protalix Biotherapeutics’s market cap is $121.99M.
When is Protalix Biotherapeutics’s upcoming earnings report date?
Protalix Biotherapeutics’s upcoming earnings report date is Nov 17, 2025 which is in 87 days.
How were Protalix Biotherapeutics’s earnings last quarter?
Protalix Biotherapeutics released its earnings results on Aug 14, 2025. The company reported $0 earnings per share for the quarter, missing the consensus estimate of $0.04 by -$0.04.
Is Protalix Biotherapeutics overvalued?
According to Wall Street analysts Protalix Biotherapeutics’s price is currently Undervalued.
Does Protalix Biotherapeutics pay dividends?
Protalix Biotherapeutics does not currently pay dividends.
What is Protalix Biotherapeutics’s EPS estimate?
Protalix Biotherapeutics’s EPS estimate is 0.06.
How many shares outstanding does Protalix Biotherapeutics have?
Protalix Biotherapeutics has 79,732,120 shares outstanding.
What happened to Protalix Biotherapeutics’s price movement after its last earnings report?
Protalix Biotherapeutics reported an EPS of $0 in its last earnings report, missing expectations of $0.04. Following the earnings report the stock price went down -5.59%.
Which hedge fund is a major shareholder of Protalix Biotherapeutics?
Currently, no hedge funds are holding shares in PLX
Protalix Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.25 (425.48% Upside)
$8.25 (425.48% Upside)
Blogger Sentiment
Bullish
PLX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 2.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $205.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.8%
Last 30 Days ▲ 7.7%
Last 30 Days ▲ 7.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
65.08%
12-Months-Change
Fundamentals
Return on Equity
15.99%
Trailing 12-Months
Asset Growth
-14.26%
Trailing 12-Months
Company Description
Protalix Biotherapeutics
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.
PLX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Protalix's significant revenue growth and promising developments in their product pipeline, particularly with Elfabrio and PRX-115. However, challenges such as decreased sales in certain regions, increased R&D expenses, and financial and tax expense increases were noted. Despite these challenges, the overall outlook remains positive due to strong partnerships and market potential.View all PLX earnings summariesPLX Stock 12 Month Forecast
Average Price Target
$8.25
▲(425.48% Upside)
Technical Analysis
Lexicon Pharmaceuticals
―
DBV Technologies SA - American
―
TuHURA Biosciences
―
Gossamer Bio
―
Terns Pharmaceuticals
―
Ownership Overview
1.48% Insiders
0.64% Mutual Funds
1.90% Other Institutional Investors
92.62% Public Companies and
Individual Investors